Companies › Shanghai Juncell Therapeutics
3 active drug programs in 10 registered trials: 5 Phase 2, 5 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GC101 TIL Autologous tumor infiltrating lymphocytes (TIL) therapy | – | Phase 2 | Non Small Cell Lung Cancer; Melanoma; Non Small Cell Lung Cancer Metastatic; Liver Cancer | Jan 2027 |
| GC203 TIL Engineered tumor infiltrating lymphocytes (TIL) with ex vivo expansion and culture | – | Phase 1 | Solid Tumors, Adult; Solid Tumor | Nov 2026 |
| PD-1 antibody PD-1 inhibitor (low-dose) | PDCD1 | Phase 1 | Solid Tumor; Perihilar Cholangiocarcinoma; Esophageal Squamous Cell Carcinoma (ESCC); Lung Cancer | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06084299 | GC101 TIL | Phase 1 | Liver Cancer | Oncology | Aug 2026 |
| NCT07256756 | GC203 TIL | Phase 1 | Solid Tumors, Adult | Oncology | Nov 2026 |
| NCT06473961 | GC101 TIL | Phase 1 | Non Small Cell Lung Cancer Metastatic | Oncology | Jan 2027 |
| NCT05430698 | PD-1 antibody | Phase 2 | Perihilar Cholangiocarcinoma | Oncology | Jan 2027 |
| NCT06375187 | GC203 TIL | Phase 1 | Solid Tumor | Oncology | May 2027 |
| NCT06375187 | PD-1 antibody | Phase 1 | Solid Tumor | Oncology | May 2027 |
| NCT07560111 | GC101 TIL | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT06703398 | GC101 TIL | Phase 2 | Melanoma | Oncology | Dec 2027 |
| NCT07559045 | PD-1 antibody | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | Oncology | Jan 2028 |
| NCT06478108 | PD-1 antibody | Phase 2 | Lung Cancer | Oncology | Dec 2028 |
Binhui Biopharmaceutical Immorna Biotherapeutics CrystalGenomics PersonGen BioTherapeutics (Suzhou) ImmVira Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.